OPEN ACCESS Freely available online

Journal of Clinical Trials

Perspective

An Overview of Diabetes Therapies in Clinical Trials

Jian Zhang*

Department of Pharmaceutical Sciences, Jilin University, Changchun, China

DESCRIPTION

Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycaemia, has seen significant advancements in therapeutic options over recent years. Clinical trials play a pivotal role in evaluating the efficacy and safety of new treatments, for improved management of this widespread condition. This article explores some of the encouraging diabetes therapies currently undergoing clinical trials.

Glp-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a transformative class of drugs for type 2 diabetes. These agents enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, contributing to better glycaemic control and weight loss. Semaglutide, an injectable GLP-1 receptor agonist, has shown impressive results in clinical trials, with significant reductions in HbA1c levels and body weight. The once-weekly formulation of semaglutide is particularly noteworthy for its convenience and efficacy.

Sglt2 inhibitors

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as dapagliflozin and empagliflozin, represent another innovative approach to diabetes management. By inhibiting renal glucose reabsorption, these drugs promote glycosuria and reduce blood glucose levels. Clinical trials have demonstrated their benefits not only in glycemic control but also in reducing cardiovascular risk and slowing the progression of chronic kidney disease. These dual benefits make SGLT2 inhibitors a valuable addition to diabetes therapy.

Dual gip/glp-1 receptor agonists

A novel class of drugs combining the actions of GLP-1 and Glucose-Dependent Insulinotropic Polypeptide (GIP) is currently under investigation. Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown remarkable efficacy in clinical trials, outperforming existing GLP-1 receptor agonists in terms of HbA1c reduction and weight loss. This dual mechanism of action holds promise for superior glycemic control and broader metabolic benefits.

Oral insulin

The development of oral insulin has been a long-sought goal in diabetes research, aiming to replace the need for injectable insulin. Recent advancements in drug delivery technologies have brought this goal closer to reality. Oral insulin formulations are designed to protect insulin from degradation in the gastrointestinal tract and enhance its absorption into the bloodstream. Clinical trials are underway to evaluate the efficacy and safety of these formulations, with early results showing promise for non-invasive insulin administration.

Gene therapy

Gene therapy represents a cutting-edge approach to diabetes treatment, with the potential to address the underlying genetic causes of the disease. One strategy involves the delivery of genes encoding insulin or other key proteins involved in glucose metabolism directly to the patient's cells. Preclinical studies have shown that gene therapy can restore normal insulin production and glucose homeostasis in animal models of diabetes. Ongoing clinical trials aim to translate these findings into human therapies, offering the possibility of a long-term cure for diabetes.

Stem cell therapy

Stem cell therapy is another frontier in diabetes research, with the goal of regenerating insulin-producing beta cells in the pancreas. Researchers are investigating various types of stem cells, including embryonic stem cells and induced pluripotent stem cells, to develop treatments that can restore endogenous insulin production. Early-phase clinical trials have shown that stem cell-derived beta cells can survive and function in diabetic patients, providing a potential pathway to disease modification and cure.

Correspondence to: Jian Zhang, Department of Pharmaceutical Sciences, Jilin University, Changchun, China, E-mail: Jian@zhang1245.cn

Received: 03-Jun-2024, Manuscript No. JCTR-24-32486; **Editor assigned:** 05-Jun-2024, Pre QC No. JCTR-24-32486; **Reviewed:** 19-Jun-2024, QC No. JCTR-24-32486; **Revised:** 26-Jun-2024, Manuscript No. JCTR-24-32486; **Published:** 03-Jul-2024, DOI: 10.35248/2167-0870.24.14.004.

Citation: Zhang J (2024) An Overview of Diabetes Therapies in Clinical Trials. J Clin Trials. S28:004.

Artificial pancreas systems

Artificial pancreas systems, also known as closed-loop insulin delivery systems, integrate Continuous Glucose Monitoring (CGM) with insulin pumps to automate insulin delivery based on real-time glucose levels. These systems aim to mimic the physiological insulin secretion of a healthy pancreas, improving glycemic control and reducing the burden of diabetes management. Recent clinical trials have demonstrated that artificial pancreas systems can significantly reduce HbA1c levels and hypoglycemia episodes, enhancing the quality of life for people with diabetes.

CONCLUSION

The landscape of diabetes therapies is rapidly evolving, with numerous innovative treatments undergoing clinical trials. From GLP-1 receptor agonists and SGLT2 inhibitors to gene and stem cell therapies, these advancements hold the promise of better glycemic control, reduced complications, and ultimately, a cure for diabetes. As clinical trials continue to progress, they offer hope for millions of individuals living with diabetes, paving the way for a future with more effective and accessible treatment options.